, May 5, 2014
/PRNewswire/ -- Elite Pharmaceuticals, Inc. (OTCQB: ELTP) develops oral sustained and controlled release products. Elite has eight commercial products currently being sold, twelve additional approved products pending manufacturing site transfer and two additional products under review pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology.
ELTP has been in business since 1990 but came under new management in August of last year. Since then the company has embarked on an expansion, including the acquisition of new drug products and development agreements with other drug companies.
The company recently entered into a financing agreement with Lincoln Park Capital that could provide adequate funding for the company in the near term. The financing is in the form of a share purchase agreement.
A full report on ELTP that includes risk factors, industry review, financial position, potential revenues, and review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link:
Copy and paste to browser may be required.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Mark Bonacci, Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
A full disclaimer can be found by viewing the full analyst report.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at firstname.lastname@example.org. For any urgent concerns or inquiries please contact us at email@example.com.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.